NCT07035860Not yet recruiting
Efficacy and Safety of Chemoimmunotherapy and Carbon Ion Radiotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer
Efficacy and Safety of Induction Chemoimmunotherapy Followed by Carbon Ion Radiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer
Source: ClinicalTrials.gov · Last updated 25 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is the first prospective clinical study to evaluate the efficacy and safety of induction chemoimmunotherapy followed by carbon ion radiotherapy and consolidation immunotherapy in patients with unresectable locally advanced non-small cell lung cancer (NSCLC). Based on this prospective study, tumor tissue, blood, urine, and stool samples from participants will be collected and analyzed to identify predictive markers of treatment response.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 34 (estimated)
- First submitted
- 16 Jun 2025
- Start date
- 16 Jun 2025
- Primary completion date
- 15 Jun 2027
- Lead sponsor
- Ji Yongling
- Diseases
- Lung cancer
- NCT number
- NCT07035860
What you commit to
- Study type: Observational
- Planned participants: 34
- From 16 Jun 2025 to the primary completion date, 15 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Active or prior autoimmune/inflammatory disorders.
Other illness
- Histological evidence of small cell lung cancer or other primary malignancies
Lab values
- EGFR, ALK, or ROS-1 gene mutations.
Other
- Inability to comply with study protocol as judged by the investigator.
Who the study is looking for
- Unresectable, locally advanced non-small cell lung cancer (according to the 8th edition of the AJCC staging system).
- No prior anti-cancer treatment.
- No significant internal medical conditions or major organ dysfunction.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhejiang Cancer Hospital Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.